Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher cataract progression ‐ 24 months compared with sham (moderate certainty).
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with sham (moderate certainty).
Intravitreal fluocinolone acetonide implant 0.19 mg may leads to higher surgery for glaucoma ‐ 24 months compared with sham (low certainty).
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes gain of three or more lines visual acuity ‐ 24 months** compared with sham (very low certainty).
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in cataract progression ‐ 24 months compared with sham (low certainty).
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes use of IOP‐lowering medications ‐ 24 months compared with sham (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in visual acuity (logMAR) ‐ 12 months (negative is better) compared with macular laser (very low certainty).
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with macular laser (low certainty).
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in retinal thickness (micron) (negative is better) compared with macular laser (very low certainty).
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher cataract progression ‐ 9 to 24 months compared with macular laser (moderate certainty).
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher use of IOP‐lowering medications ‐ 9 to 24 months compared with macular laser (moderate certainty).
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in surgery for glaucoma ‐ 9 to 24 months compared with macular laser (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in central retinal thickness (micron) ‐ 12 months (negative… compared with antiVEGF (very low certainty).